ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 8 for:    GenSpera

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02381236
Recruitment Status : Completed
First Posted : March 6, 2015
Last Update Posted : February 24, 2017
Sponsor:
Information provided by (Responsible Party):
GenSpera, Inc.

Brief Summary:
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: G-202 Phase 2

Detailed Description:
More than one-third of patients with localized high-risk prostate cancer who undergo radical prostatectomy eventually relapse with distant disease and some data suggest that neoadjuvant treatment in this patient population may be helpful. This study is based on prodrug tumor targeting, in which an inactive form of a toxic agent is administered systemically and gets activated in specific locations in the body, resulting in higher concentrations of the cytotoxic form at the tumor location. G-202 is a prodrug that is activated in prostate cancer tissue and in the blood vessels of tumors, but not normal tissue; once activated, G-202 leads to disruption of intracellular calcium levels and subsequent induction of apoptosis. Thus, G-202 is expected to bring about cell death in prostate cancer cells and to destroy the blood supply of prostate tumors. G-202 has led to disease stabilization in some patients, but the drug has not been evaluated in the neoadjuvant setting. This single-arm, open-label Phase II clinical trial will evaluate the safety and activity of G-202 in patients with localized high-risk prostate cancer prior to radical prostatectomy. Through its effects on the neovasculature of tumors, G-202 is anticipated to disrupt the blood supply of the prostate tumor, resulting in decreased perfusion and subsequent tumor volume. The primary endpoint of this study is evaluation of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: G-202-005: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 Administered in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate
Study Start Date : February 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : February 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: G-202
G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
Drug: G-202
G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
Other Name: Mipsagargin



Primary Outcome Measures :
  1. Volume of the prostate using multiparametric prostate magnetic resonance imaging (mpMRI) [ Time Frame: 12 weeks from first administration of G-202 ]
    mpMRI performed after 3 cycles of treatment prior to prostatectomy

  2. Perfusion of the prostate using multiparametric prostate magnetic resonance imaging (mpMRI) [ Time Frame: 12 weeks from first administration of G-202 ]
    mpMRI performed after 3 cycles of treatment prior to prostatectomy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ECOG Performance Status < 2
  • Histological confirmation of prostatic adenocarcinoma that is confined to the prostate without evidence of regional and/or distant metastasis
  • Clinical stage T1c or T2a with high-grade disease (Gleason 8-10) on initial biopsy, clinical stage T2b-T2c with Gleason grade 7 (4+3), or clinical stage T3
  • Negative bone scan and CT of chest and abdomen within 6 weeks of first infusion of G-202
  • Candidate for radical prostatectomy
  • Adequate hematologic function (ANC ≥ 1200/mm3, hemoglobin ≥ 8.5 g/dL, platelets ≥ 75,000/mm3)
  • Adequate hepatic function (albumin ≥ 2.8 g/dL, AST and ALT ≤ 5 x ULN, total bilirubin < 2 mg/dL)
  • Adequate renal function (proteinuria level ≤ 2+, serum creatinine ≤ 1.5 x ULN)
  • Acceptable coagulation profile (no history of substantial non-iatrogenic bleeding diatheses, INR ≤ 2.3, aPTT ≤ 1.5 x ULN)
  • Ejection fraction (LVEF) ≥ 45% measured by echocardiogram
  • Willing to use acceptable methods of contraception to avoid pregnancy

Exclusion Criteria:

  • Prostatic adenocarcinoma with neuroendocrine differentiation or small cell features
  • Unable to tolerate mpMRI
  • Surgical resection or major surgery within 4 weeks or stereotactic biopsy within 1 week prior to first G-202 treatment
  • Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy, or other investigational status drug for prostatic adenocarcinoma
  • Currently requiring systemic administration of antibiotics or chronic administration of anti-viral agents
  • Use of anti-coagulants is limited to local use for control of central line patency
  • History or evidence of cardiac risk
  • Uncontrolled cardiac or coronary artery disease
  • Uncontrolled hypertension or hypertension requiring treatment with more than 2 anti-hypertensive agents
  • Severe or uncontrolled medical disease
  • Severe gastrointestinal bleeding within 12 weeks prior to treatment with G-202
  • Known history of HIV, hepatitis B or hepatitis C
  • Use of herbal products that may decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids
  • Documentation of keratosis follicularis
  • Requirement for chronic use of medications known to be strong inhibitors or inducers of cytochrome (CYP3A4) iso-enzymes
  • Another primary malignancy, except non-melanoma skin cancer, that has not been in remission for at least 2 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02381236


Locations
United States, Texas
University of Texas Health Sciences Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
GenSpera, Inc.
Investigators
Principal Investigator: Robert Amato, D.O. University of Texas Health Sciences Center at Houston

Responsible Party: GenSpera, Inc.
ClinicalTrials.gov Identifier: NCT02381236     History of Changes
Other Study ID Numbers: G-202-005
First Posted: March 6, 2015    Key Record Dates
Last Update Posted: February 24, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases